We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties. You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies. In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Hims & Hers Stock Surges 69.2% in Three Months: What's Next?
Read MoreHide Full Article
Hims & Hers Health, Inc.’s (HIMS - Free Report) investors have been experiencing some short-term gains from the stock of late. Shares of the San Francisco, CA-based health and wellness platform have surged 69.2% in the past three months, outperforming the industry’s 14.5% gain. In the same time frame, the stock outperformed the sector and S&P 500’s 3.7% decline and 6.5% growth, respectively.
Two major developments of HIMS in recent months include the announcement of its third-quarter 2024 results and the announcement that the company’s customers can have convenient, nutrient-packed meal replacement bars and shakes delivered to them through the Hims & Hers platform (both in November 2024).
The company reported robust improvement of the top and bottom lines in the third quarter of 2024. Strength in both Online and Wholesale revenue channels and increase in Subscribers, Monthly Online Revenue per Average Subscriber, Average Order Value and Net Orders during the quarter were also recorded.
Per management, HIMS’ model is rapidly gaining scale, thereby driving top-line growth, improving profitability and strong cash flow. On the earnings call, management confirmed that the company launched access to personalized titration schedules and dosing for semaglutide within weight loss during the third quarter.
HIMS Three Months Price Comparison
Image Source: Zacks Investment Research
Over the past three months, the stock’s performance has remained strong, similar to that of its peers like Teladoc Health, Inc. (TDOC - Free Report) and Abbott Laboratories (ABT - Free Report) . TDOC’s shares have gained 15%, while ABT’s shares have gained 12.8% in the same time frame.
Despite several challenges within the health and wellness market, including workforce-related complications and health epidemics or pandemics, the favorable estimates indicate that the company might be able to maintain the positive market momentum at present.
HIMS expects revenues for the fourth quarter of 2024 and the full year in the bands of $465 million-$470 million (reflecting an uptick of 89-91%) and $1.460 billion-$1.465 billion (representing growth of 67-68% from 2023 levels), respectively. The Zacks Consensus Estimate for the time frames is currently pegged at $471.4 million and $1.47 billion, respectively. The estimates indicate 91.2% and 68.2% improvements, respectively, from the year-ago and comparable 2023 periods. Additionally, the Zacks Consensus Estimate for revenues and earnings per share in 2025 is currently pegged at $2.07 billion and 52 cents, respectively.
Hims & Hers has a unique mix of a clinically-focused electronic medical record system, digital prescriptions and cloud pharmacy fulfillment, each with multiple growth drivers promising robust growth potential.
During the third quarter of 2024, Hims & Hers continued to focus on adding net new subscribers and expanding its offerings, and the progress is evident so far. On top of this, the stock seems well-positioned to navigate the current macroeconomic climate.
HIMS’ Strong Fundamentals Weigh In
Hims & Hers is consistently witnessing strong market acceptance of its range of curated prescription and non-prescription health and wellness products and services. The company has been focusing on providing access to high-quality, personalized solutions at an affordable price. This is significantly driving the number of net subscribers.
The company ended the third quarter of 2024 with 2 million subscribers (up 43.5% year over year), adding more than 180,000 net subscribers to the platform. HIMS’ subscriber base, excluding GLP-1s, grew approximately 40% year over year. Per management, continued innovation across the company’s portfolio of personalized solutions was a key catalyst behind this expansion. Hims & Hers believes that the growing emphasis on personalized solutions, along with the maturation of newer customer groups introduced to favorable pricing models, is enhancing its retention rates. Additionally, the company is witnessing continued success in acquiring customers through more cost-effective channels as awareness of the Hims & Hers brands grows.
On the third-quarter earnings call this month, management shared its plan to bring liraglutide, the first generic GLP-1 in the market, to the platform in 2025. HIMS expects to complete test and batch validation and confirm certificates of authenticity over the next few months. The company also feels that as it continues to broaden the variety of solutions across specialties and elevate the number of multi-condition personalized treatments, the number of multi-condition subscribers will continue to increase. In 2025, management expects to elevate the consumer experience for Hims & Hers’ multi-specialty subscribers through technological advancements on its platform.
Hims & Hers’ Product Availability
Hims & Hers’ continued focus on strengthening its comprehensive weight loss offerings, such as announcing the doorstep delivery of daily meal replacement bars and shakes in November 2024, also looks promising. The company aims to aid its customers reach and maintain their health and wellness goals.
HIMS, in September, had announced access to the most common compounded GLP-1 subscriptions for $99 a month for eligible U.S. military, veterans, teachers, nurses and first responders. The company’s efforts to ease access to products are likely to aid it in expanding its customer base, which looks promising.
HIMS’ Stock Valuation
HIMS’ forward 12-month P/S of 3.3X is lower than the industry’s average of 6X but is higher than its five-year median of 2.5X.
Image Source: Zacks Investment Research
Hims & Hers’ Estimate Movement
Estimates for Hims & Hers’ 2025 earnings have moved 4% north to 52 cents in the past 60 days.
Image Source: Zacks Investment Research
Our Final Take
There is no denying that Hims & Hers sits favorably in terms of core business strength, earnings prowess, robust financial footing and global opportunities. The Zacks Rank #3 (Hold) stock’s strong core growth prospects present a good reason for existing investors to retain shares for potential future gains. New investors are also likely to be motivated to add the stock following the current surge in share prices. You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.
For those exploring to make new additions to their portfolios, the valuation indicates superior performance expectations compared with its industry peers. It is still valued lower than the industry, which suggests potential room for growth if it can align more closely with overall market performance. However, if investors are already holding the stock, it would be prudent to hold on to it at present. The favorable Zacks Style Score with a Growth Score of A suggests continued uptrend potential for HIMS.
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Bigstock
Hims & Hers Stock Surges 69.2% in Three Months: What's Next?
Hims & Hers Health, Inc.’s (HIMS - Free Report) investors have been experiencing some short-term gains from the stock of late. Shares of the San Francisco, CA-based health and wellness platform have surged 69.2% in the past three months, outperforming the industry’s 14.5% gain. In the same time frame, the stock outperformed the sector and S&P 500’s 3.7% decline and 6.5% growth, respectively.
Two major developments of HIMS in recent months include the announcement of its third-quarter 2024 results and the announcement that the company’s customers can have convenient, nutrient-packed meal replacement bars and shakes delivered to them through the Hims & Hers platform (both in November 2024).
The company reported robust improvement of the top and bottom lines in the third quarter of 2024. Strength in both Online and Wholesale revenue channels and increase in Subscribers, Monthly Online Revenue per Average Subscriber, Average Order Value and Net Orders during the quarter were also recorded.
Per management, HIMS’ model is rapidly gaining scale, thereby driving top-line growth, improving profitability and strong cash flow. On the earnings call, management confirmed that the company launched access to personalized titration schedules and dosing for semaglutide within weight loss during the third quarter.
HIMS Three Months Price Comparison
Image Source: Zacks Investment Research
Over the past three months, the stock’s performance has remained strong, similar to that of its peers like Teladoc Health, Inc. (TDOC - Free Report) and Abbott Laboratories (ABT - Free Report) . TDOC’s shares have gained 15%, while ABT’s shares have gained 12.8% in the same time frame.
Despite several challenges within the health and wellness market, including workforce-related complications and health epidemics or pandemics, the favorable estimates indicate that the company might be able to maintain the positive market momentum at present.
HIMS expects revenues for the fourth quarter of 2024 and the full year in the bands of $465 million-$470 million (reflecting an uptick of 89-91%) and $1.460 billion-$1.465 billion (representing growth of 67-68% from 2023 levels), respectively. The Zacks Consensus Estimate for the time frames is currently pegged at $471.4 million and $1.47 billion, respectively. The estimates indicate 91.2% and 68.2% improvements, respectively, from the year-ago and comparable 2023 periods. Additionally, the Zacks Consensus Estimate for revenues and earnings per share in 2025 is currently pegged at $2.07 billion and 52 cents, respectively.
Hims & Hers has a unique mix of a clinically-focused electronic medical record system, digital prescriptions and cloud pharmacy fulfillment, each with multiple growth drivers promising robust growth potential.
During the third quarter of 2024, Hims & Hers continued to focus on adding net new subscribers and expanding its offerings, and the progress is evident so far. On top of this, the stock seems well-positioned to navigate the current macroeconomic climate.
HIMS’ Strong Fundamentals Weigh In
Hims & Hers is consistently witnessing strong market acceptance of its range of curated prescription and non-prescription health and wellness products and services. The company has been focusing on providing access to high-quality, personalized solutions at an affordable price. This is significantly driving the number of net subscribers.
The company ended the third quarter of 2024 with 2 million subscribers (up 43.5% year over year), adding more than 180,000 net subscribers to the platform. HIMS’ subscriber base, excluding GLP-1s, grew approximately 40% year over year. Per management, continued innovation across the company’s portfolio of personalized solutions was a key catalyst behind this expansion.
Hims & Hers believes that the growing emphasis on personalized solutions, along with the maturation of newer customer groups introduced to favorable pricing models, is enhancing its retention rates. Additionally, the company is witnessing continued success in acquiring customers through more cost-effective channels as awareness of the Hims & Hers brands grows.
On the third-quarter earnings call this month, management shared its plan to bring liraglutide, the first generic GLP-1 in the market, to the platform in 2025. HIMS expects to complete test and batch validation and confirm certificates of authenticity over the next few months. The company also feels that as it continues to broaden the variety of solutions across specialties and elevate the number of multi-condition personalized treatments, the number of multi-condition subscribers will continue to increase. In 2025, management expects to elevate the consumer experience for Hims & Hers’ multi-specialty subscribers through technological advancements on its platform.
Hims & Hers’ Product Availability
Hims & Hers’ continued focus on strengthening its comprehensive weight loss offerings, such as announcing the doorstep delivery of daily meal replacement bars and shakes in November 2024, also looks promising. The company aims to aid its customers reach and maintain their health and wellness goals.
HIMS, in September, had announced access to the most common compounded GLP-1 subscriptions for $99 a month for eligible U.S. military, veterans, teachers, nurses and first responders. The company’s efforts to ease access to products are likely to aid it in expanding its customer base, which looks promising.
HIMS’ Stock Valuation
HIMS’ forward 12-month P/S of 3.3X is lower than the industry’s average of 6X but is higher than its five-year median of 2.5X.
Image Source: Zacks Investment Research
Hims & Hers’ Estimate Movement
Estimates for Hims & Hers’ 2025 earnings have moved 4% north to 52 cents in the past 60 days.
Image Source: Zacks Investment Research
Our Final Take
There is no denying that Hims & Hers sits favorably in terms of core business strength, earnings prowess, robust financial footing and global opportunities. The Zacks Rank #3 (Hold) stock’s strong core growth prospects present a good reason for existing investors to retain shares for potential future gains. New investors are also likely to be motivated to add the stock following the current surge in share prices. You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.
For those exploring to make new additions to their portfolios, the valuation indicates superior performance expectations compared with its industry peers. It is still valued lower than the industry, which suggests potential room for growth if it can align more closely with overall market performance. However, if investors are already holding the stock, it would be prudent to hold on to it at present. The favorable Zacks Style Score with a Growth Score of A suggests continued uptrend potential for HIMS.